Möchten Sie immer auf dem neuesten Stand bleiben?

Fourth-quarter and full-year 2025 Rezdiffra® (resmetirom) net sales of $321.1 million and $958.4 million, respectively As of year-end 2025, more than 36,250 patients on Rezdiffra Built...

Company advances its leadership in MASH with an expanded pipeline, which now includes more than 10 programs at multiple stages of development, anchored by Rezdiffra® (resmetirom) as the foundational...

Agreement expands Madrigal’s pipeline and strengthens its leadership in pioneering MASH therapiesDGAT-2 inhibition represents a complementary mechanism of action with Rezdiffra® (resmetirom) for...

Improvements observed in key non-invasive markers of fibrosis across treatment arms versus placebo, with continued reductions from 24-week timepoint Additional weight loss from 24 to 48 weeks with...

CONSHOHOCKEN, Pa., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in the J.P. Morgan Annual Healthcare Conference...

The Company expects to initiate first-in-human study in early 2026, with initial data anticipated H2 2026 Clinical Trial Application (CTA) submission marks the advancement of Tangram’s GalOmic RNAi...

CONSHOHOCKEN, Pa., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in fireside chats at three upcoming investor...

Rezdiffra® treatment significantly improved liver stiffness, fibrosis biomarkers, and markers of clinically significant portal hypertension risk in patients with compensated MASH cirrhosis Rezdiffra...

Phase 2 M-ACCEL trial in MASH met primary endpoint, with statistically significant reductions in liver fat observed in all HU6 treatment groups

Gyre Therapeutics Reports Third Quarter 2025 and Year-to-Date Financial Results and Provides Business Update